Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle

被引:34
作者
Wells, KE [1 ]
Fletcher, S
Mann, CJ
Wilton, SD
Wells, DJ
机构
[1] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Neuromuscular Dis, Div Neurosci & Psychol Med,Gene Targeting Unit, London W6 8RP, England
[2] QEII Med Ctr, Australian Neuromuscular Res Inst, Expt Mol Med Unit, Nedlands, WA 6009, Australia
基金
英国医学研究理事会;
关键词
antisense oligonucleotide; electrotransfer; dystrophin; Duchenne muscular dystrophy; Mdx;
D O I
10.1016/S0014-5793(03)00904-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of antisense oligonucleotides (AOs) to induce exon skipping leading to generation of an in-frame dystrophin protein product could be of benefit in around 70% of Duchenne muscular dystrophy patients. We describe the use of hyaluronidase enhanced electrotransfer to deliver uncomplexed 2'-O-methyl modified phosphorothioate AO to adult dystrophic mouse muscle, resulting in dystrophin expression in 20-30% of fibres in tibialis anterior muscle after a single injection. Although expression was transient, many of the corrected fibres initially showed levels of dystrophin expression well above the 20% of endogenous previously shown to be necessary for phenotypic correction of the dystrophic phenotype. (C) 2003 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:145 / 149
页数:5
相关论文
共 29 条
[1]   Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy [J].
Aartsma-Rus, A ;
Bremmer-Bout, M ;
Janson, AAM ;
den Dunnen, JT ;
van Ommen, GJB ;
van Deutekom, JCT .
NEUROMUSCULAR DISORDERS, 2002, 12 :S71-S77
[2]   Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy [J].
Ahmad, A ;
Brinson, M ;
Hodges, BL ;
Chamberlain, JS ;
Amalfitano, A .
HUMAN MOLECULAR GENETICS, 2000, 9 (17) :2507-2515
[3]  
Boado RJ, 2000, J PHARMACOL EXP THER, V295, P239
[4]   The efficient expression of intravascularly delivered DNA in rat muscle [J].
Budker, V ;
Zhang, G ;
Danko, I ;
Williams, P ;
Wolff, J .
GENE THERAPY, 1998, 5 (02) :272-276
[5]   Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Δ48-50 DMD cells [J].
De Angelis, FG ;
Sthandier, O ;
Berarducci, B ;
Toso, S ;
Galluzzi, G ;
Ricci, E ;
Cossu, G ;
Bozzoni, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (14) :9456-9461
[6]   Screening for antisense modulation of dystrophin pre-mRNA splicing [J].
Dickson, G ;
Hill, V ;
Graham, IR .
NEUROMUSCULAR DISORDERS, 2002, 12 :S67-S70
[7]   Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides [J].
Dunckley, MG ;
Manoharan, M ;
Villiet, P ;
Eperon, IC ;
Dickson, G .
HUMAN MOLECULAR GENETICS, 1998, 7 (07) :1083-1090
[8]   Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy [J].
Ferrer, A ;
Wells, KE ;
Wells, DJ .
GENE THERAPY, 2000, 7 (17) :1439-1446
[9]   Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides [J].
Friedman, KJ ;
Kole, J ;
Cohn, JA ;
Knowles, MR ;
Silverman, LM ;
Kole, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (51) :36193-36199
[10]   High-efficiency plasmid gene transfer into dystrophic muscle [J].
Gollins, H ;
McMahon, J ;
Wells, KE ;
Wells, DJ .
GENE THERAPY, 2003, 10 (06) :504-512